Search
Company Statements Media Contact Email Alerts
Events & Presentations Financials Stock Information Governance Resources
Patients Team Community Environment Compliance & Transparency
Our Locations Medical Information
magnifying glass icon
Incyte
  • Our Company
  • What We Do
  • Culture & Careers
  • Patient Resources
  • HCP Resources
  • Our Stories
  • Our Company
    • Our Leadership
  • What We Do
    • Portfolio
      • Molecules in Development
      • Clinical Trials
    • Oncology
      • Approved Therapies
      • HCP Resources
    • Dermatology
      • Approved Therapies
      • HCP Resources
    • Partnerships
  • Culture & Careers
    • Open Positions
    • Incyte Involved
    • Inclusion
  • Patient Resources
  • HCP Resources
  • Our Stories
  • magnifying glass icon
  • Our Company
    • magnifying glass icon
    • our company
    • our leadership
  • What We Do
    • magnifying glass icon
    • what we do
    • portfolio
    • oncology
    • dermatology
    • partnerships
  • Culture & Careers
    • magnifying glass icon
    • culture & careers
    • open positions
    • incyte involved
    • inclusion
  • Patient Resources
  • HCP Resources
  • Our Stories
  • News
    • magnifying glass icon< input type = 'text' class='searchInputContainer-cust search-input-mobile' placeholder='Search' autofocus=''>
    • our company
    • Company Statements
    • Media Contact
    • E-Mail Alerts
  • Investors
    • magnifying glass icon< input type = 'text' class='searchInputContainer-cust search-input-mobile' placeholder='Search' autofocus=''>
    • our company
    • Events & Presentations
    • Financials
    • Stock Information
    • Governance
    • Resources
  • Responsibility
    • magnifying glass icon< input type = 'text' class='searchInputContainer-cust search-input-mobile' placeholder='Search' autofocus=''>
    • Patients
    • Team
    • Community
    • Environment
    • Compliance & Transparency
  • Contact Us
    • magnifying glass icon< input type = 'text' class='searchInputContainer-cust search-input-mobile' placeholder='Search' autofocus=''>
    • our company
    • Our Locations
    • Medical Information
  • United States

Incyte International Locations

NORTH AMERICA—
HEADQUARTERS

DENMARK

ITALY

SPAIN

UNITED KINGDOM

EUROPE—
HEADQUARTERS

FINLAND

JAPAN

SWEDEN

AUSTRIA

FRANCE

THE NETHERLANDS

SWITZERLAND

CANADA

GERMANY

NORWAY

PORTUGAL

Close

Home breadcrumb separator Our Storiesbreadcrumb separatorStory10
Back
Image of patient and healthcare professional

Understanding Diffuse Large
B-cell Lymphoma (DLBCL)

A blood cancer diagnosis, which happens approximately every three minutes in the U.S., is life altering. It can be overwhelming for patients and caregivers to understand what it means for them and the future.

Blood cancers fall into one of several categories, including leukemia, lymphoma, myeloma, and myeloproliferative disorders. Diffuse large B-cell lymphoma (DLBCL), a cancer that affects certain white blood cells called B cells, is the most common type of non-Hodgkin lymphoma in adults worldwide.

Patients’ experiences and needs are unique, and through our conversations with patients living with DLBCL, the path to diagnosis is varied. Some thought they had common ailments like a muscle strain or fatigue, until the symptoms worsened to the point where they were unable to go about their daily lives–for example, taking care of their basic needs independently, getting out of bed or driving a car.

Lance Leopold, M.D., Group Vice President, Clinical Development Hematology and Oncology at Incyte

At Incyte we are committed to supporting those living with blood cancers, including DLBCL, by raising much-needed awareness of these conditions.

Incyte’s Lance Leopold, M.D., Group Vice President, Clinical Development Hematology and Oncology shares key facts for those with DLBCL.

 

Q: What is DLBCL?

Lance Leopold: DLBCL is a fast-growing cancer that affects white blood cells known as B cells. B cells normally help the immune system defend against infections caused by bacteria or viruses. However, in DLBCL, abnormal B cells become cancerous. This means that they multiply uncontrollably and live longer than normal cells.

Q: Who is affected?

Lance Leopold: DLBCL is most frequently diagnosed among those over the age of 65, however it can occur at any age. It’s also more commonly found in men as they are about 1.5 times more likely to have DLBCL than women. Additionally, certain medications or conditions that suppress the immune system can increase the likelihood of developing the condition.

Q: What are common symptoms of DLBCL?

Lance Leopold: Symptoms of DLBCL are often nonspecific and can include: fever for no known reason, pain in the chest, abdomen, or bones for no known reason, feeling very tired, weight loss for no known reason, skin rash or itchy skin, and drenching night sweats. If you’re experiencing symptoms like this, be sure to talk to your healthcare provider.

Q: The terms “relapsed” and “refractory” are often used in reference to DLBCL. What do they mean?

Lance Leopold: Unfortunately, it’s not uncommon for people with DLBCL to respond to initial therapy but then experience a relapse, meaning the cancer returns, or for the cancer to become refractory (not respond to treatment). If this has happened to you or a loved one, know you are not alone as this occurs in up to 50% of cases.

Recently, there have been exciting advances in treating relapsed and refractory DLBCL. Contact your health care provider for additional information.

Healthcare decisions following any diagnosis, including DLBCL, are personal and needs and goals will be different for every patient. Honest conversations between patients and their care team can often be important for determining the best approach.

For those with DLBCL in the U.S. who don’t know where to start, visit DLBCL Support Source to view available resources.

Related Content

A Day in the Life—Jennifer Harris

Jennifer Harris, Associate Director of Drug Metabolism and Pharmacokinetics (DMPK) at Incyte

View Story

Serving Patients Through Innovation

Incyte BioPlant facility in Yverdon-les-Bains, Switzerland

View Story

You are now leaving Incyte.com

DO YOU WANT TO CONTINUE?

YES, Take Me There
NO, I Changed My Mind
Incyte © 2012-2023 Incyte.
  • Facebook Icon
  • LinkedIn Icon
  • Twitter Icon
  • Youtube Icon
  • Legal Notice
  • Privacy Policy
  • Cookie Policy
  • Suppliers
  • Site Map